144 ·Filed Apr 8, 2026

IMCR

Immunocore Holdings plc
NEUTRAL
Impact 3/10
Horizondays Processed5mo ago SEC0001974494-26-000149
Form 144 — notice of proposed sale of securities
Actionable Insight • Neutral

This is a routine insider transaction by a non-executive affiliate; traders should monitor for actual execution but no immediate price impact is expected. The sale represents a small fraction of the company's $1.5B market cap and does not signal material concern.

DirectionNeutral
Confidencehigh
Horizondays
Final — all horizons settled through T+60d
IMCR ▲ +2.04% at T+60d
NEUTRAL call ✓ call won +2.04% · α vs SPY -8.42% · entry $31.85 → $32.50
Entry anchored
Apr 8, 03:57 PM ET
via exchange tick
T+1d
-0.13%
call -0.13% · α -0.70%
$31.81
settled 6mo ago
T+5d
-0.66%
call -0.66% · α -4.18%
$31.64
settled 6mo ago
T+20d
-9.45%
call -9.45% · α -18.00%
$28.84
settled 5mo ago
T+60d
+2.04%
call +2.04% · α -8.42%
$32.50
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

David Berman, an affiliate of Immunocore Holdings plc, filed a Form 144 to notify intent to sell 25,000 ADRs, representing approximately $796,250 based on current market value. The sale is planned for April 9, 2026, via a cashless exercise and sale through J.P. Morgan Securities LLC.

Key Facts

  • Reporting person: David Berman, identified as an affiliate of the company
  • Number of securities intended for sale: 25,000 ADRs
  • Estimated value of the proposed sale: $796,250 (based on $31.85 per ADR)
  • Planned sale date: April 9, 2026
  • Method of sale: Same-day cashless exercise and sale
  • Broker: J.P. Morgan Securities LLC acting as agent and attorney in fact

Financial Impact

Approximately $796,250 in ADRs to be sold

dilutionshare_countmarket_sentiment

Risk Factors

  • Potential short-term negative sentiment if market interprets sale as lack of confidence
  • Execution risk that sale may occur at a different volume or price than disclosed

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001974494-26-000149
Document: 0001974494-26-000149-index.html0001974494-26-000149
Document: 0001974494-26-000149.txt0001974494-26-000149
7 reports for IMCR
Performance horizon
75% Hit rate 3 of 4 directional calls best @ T+60▲ +28.39%May 31, 2026
Filters
Rows
Reports for IMCR — sortable, filterable
TypeNow
Sep 14, 2026
18d ago
8-K
BULLISH ★ 6/10
$32.46 $32.18▼ −0.86%▼ −0.97%$29.71 (−8.47%)
Aug 6, 2026
8w ago
8-K
MIXED ★ 5/10
$34.50 $34.20▼ −0.87%▼ −2.08%$29.71 (−13.88%)
May 31, 2026
17w ago
Press Release
BULLISH ★ 6/10
$29.13 $28.29▼ −2.88%▼ −0.13%$29.71 (+1.99%)
Apr 19, 2026
23w ago
Press Release
BULLISH ★ 8/10
$31.46 $28.56▼ −9.22%▼ −10.13%$29.71 (−5.56%)
Apr 8, 2026
25w ago
144
NEUTRAL ★ 3/10
$31.85 $31.64▼ −0.66%▼ −4.18%$29.71 (−6.72%)
Mar 17, 2026
28w ago
Press Release
NEUTRAL ★ 5/10
$30.04 $30.28▲ +0.80%▲ +1.51%$29.71 (−1.10%)
Feb 25, 2026
31w ago
8-K
BULLISH ★ 7/10
$32.16 $33.73▲ +4.88%▲ +5.98%$29.71 (−7.62%)
Showing 7 of 7

US Market Status

Market Closed — Opens Mon (64h 9m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access